Monarch LifeSciences Enters Agreement with GeneGo to Provide Pathway Analysis Services Using 1-2-3 Workflow
News Jun 19, 2007
GeneGo, Inc. has announced that Monarch LifeSciences will be offering pathway analysis add on services to their customers. Monarch is a contract research organization with expertise in protein biomarker discovery, development and validation.
The 1-2-3 Workflow from GeneGo automatically uploads proteomics data, compares the datasets, identifies common, similar and unique components of the datasets, conducts enrichment analysis in multiple ontologies such as diseases, canonical pathways and functional processes; calculates the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report.
"We are very pleased to be working with Monarch as they offer excellent proteomics services, which is a growing OMICs field," said Julie Bryant, GeneGo's VP of Business Development. "Our goal in development of 1-2-3 Workflow was to adapt our functional data analysis technology for occasional users, which means automation and ease of use without a compromise on quality. We believe that Monarch LifeSciences' customers will be very happy with the analysis provided."
"Our goal is to provide our customers with reliable proteomics data that can easily integrate into their research programs," said Lauri Caviston, Monarch LifeSciences' VP of Business Development. "GeneGo provides an excellent tool for taking the data we generate to the next level."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.